By establishing innovative experiment tools combining in vitro and in vivo, gain- and loss-of-function, genetic and pharmacological approaches, this study has identified and characterized PARP2 deficiency as a mediator of breast cancer bone metastasis that functions via multiple mechanisms. This evidence concerns the gene PARP2 and breast carcinoma.